Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • Re-engineering anti-CTLA-4 ant...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
Re-engineering anti-CTLA-4 antibodies for enhancing cancer immunotherapy efficacy and safety

Re-engineering anti-CTLA-4 antibodies for enhancing cancer immunotherapy efficacy and safety

Bibliographic Details
Main Author: Sharvesh Raj Seeruttun
Format: Article
Language:English
Published: AIMS Press 2019-09-01
Series:AIMS Genetics
Online Access:https://www.aimspress.com/article/10.3934/genet.2019.3.64/fulltext.html
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

https://www.aimspress.com/article/10.3934/genet.2019.3.64/fulltext.html

Similar Items

  • Equibalancing immune‐related adverse events and anticancer activity of immune checkpoint inhibitors
    by: Sharvesh Raj Seeruttun
    Published: (2019-10-01)
  • Eclipsing Toxicity, Enhancing Efficacy: Clofazimine’s Vanguard in the Realm of Anti-PD-1 and CTLA-4 Immunotherapy
    by: Ruirong Tan, et al.
    Published: (2024-01-01)
  • Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy
    by: Xin Su, et al.
    Published: (2024-08-01)
  • Anti-CTLA-4 antibodies in cancer immunotherapy: selective depletion of intratumoral regulatory T cells or checkpoint blockade?
    by: Fei Tang, et al.
    Published: (2018-04-01)
  • Anti-CTLA-4 nanobody as a promising approach in cancer immunotherapy
    by: Mehregan Babamohamadi, et al.
    Published: (2024-01-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs